EGFR and non-small cell lung carcinoma: TargomiR EDVs coated with IgG-IgG (EDV, Figure 1g, anchored via S. Typhimurium O-antigen on the minicell surface, and targeting EGFR) and loaded with a miR-16-based miRNA-mimic were used against MPM and NSCLC in a phase 1 trial.